Trial Profile
The Influence of Combined Therapy with Nebivolol and Lercanidipine on Left Ventricular Diastolic Function and Hypertrophy in Patients with Essential Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Lercanidipine (Primary) ; Nebivolol (Primary)
- Indications Essential hypertension; Left ventricular dysfunction; Left ventricular hypertrophy
- Focus Therapeutic Use
- 02 Sep 2015 New trial record